This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation Social Bookmarking                            What's this?

Consensus Statements on Radiation Therapy of Prostate Cancer: Guidelines for Prostate Re-Biopsy After Radiation and for Radiation Therapy With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy

From the American Society for Therapeutic Radiology and Oncology, Reston, VA.

Address reprint requests to W.U. Shipley, MD, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114.

PURPOSE: To develop evidence-based guidelines for (1) prostate re-biopsy after radiation and (2) radiation therapy with rising prostate-specific antigen (PSA) levels after radical prostatectomy in the management of patients with localized prostatic cancer.

DESIGN: The American Society of Therapeutic Radiology and Oncology (ASTRO) challenged a multidisciplinary consensus panel to address consensus on specific issues in each of the two topics. Four well-analyzed patient data sets were presented for review and questioning by the panel. The panel sought criteria that would be valid for patients in standard clinical practice as well as for patients enrolled in clinical trials. Subsequent to an executive session that followed these presentations, the panel presented its consensus guidelines.

RESULTS AND CONCLUSIONS: Based on the data presented, the prostate re-biopsy negative rates ranged from 62% to 80% for patients with stage T1-2 tumors. The panel judged that prostate re-biopsy is not necessary as standard follow-up care and that the absence of a rising PSA level after radiation therapy is the most rigorous end point of total tumor eradication. Further, the panel judged that re-biopsy may be an important research tool. Based on the data presented, the long-term (5 years or more) PSA remission rate after salvage radiation therapy ranges from 27% to 45%. The panel requested results from prospective randomized trials to evaluate optimally this information. The panel judged that the total dose of radiation should be 64 Gy or slightly higher and that, in patients with or without radiation therapy, there is no standard role for androgen suppressant therapy for rising PSA values after prostatectomy.

Presented at the American Society for Therapeutic Radiology and Oncology Consensus Conference for Prostate Cancer, September 6, 1997, Atlanta, GA.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. P. Brown, D. S. Wendler, K. A. Camphausen, F. G. Miller, and D. Citrin Performing Nondiagnostic Research Biopsies in Irradiated Tissue: A Review of Scientific, Clinical, and Ethical Considerations J. Clin. Oncol., August 20, 2008; 26(24): 3987 - 3994. [Abstract] [Full Text] [PDF]

				F. Shimizu, A. Igarashi, T. Fukuda, Y. Kawachi, S. Minowada, Y. Ohashi, and M. Fujime Decision Analyses in Consideration of Treatment Strategies for Patients with Biochemical Failure After Curative Therapy on Clinically Localized Prostate Cancer in the Prostate-Specific Antigen Era Jpn. J. Clin. Oncol., October 22, 2007; (2007) hym105v1. [Abstract] [Full Text] [PDF]

				L. Y. Khor, J. Moughan, T. Al-Saleem, E. H. Hammond, V. Venkatesan, S. A. Rosenthal, M. A. Ritter, H. M. Sandler, G. E. Hanks, W. U. Shipley, et al. Bcl-2 and Bax Expression Predict Prostate Cancer Outcome in Men Treated with Androgen Deprivation and Radiotherapy on Radiation Therapy Oncology Group Protocol 92-02 Clin. Cancer Res., June 15, 2007; 13(12): 3585 - 3590. [Abstract] [Full Text] [PDF]

				A. B. Jani, S. L. Liauw, and M. J. Blend The Role of Indium-111 Radioimmunoscintigraphy in Post-Radical Retropubic Prostatectomy Management of Prostate Cancer Patients Clin. Med. Res., June 1, 2007; 5(2): 123 - 131. [Abstract] [Full Text] [PDF]

				T. Sasaki, K. Nakamura, K. Ogawa, H. Onishi, Y. Otani, M. Koizumi, Y. Shioyama, T. Teshima, and The Japanese Patterns of Care Study Working Subgro Postoperative Radiotherapy for Patients with Prostate Cancer in Japan; Changing Trends in National Practice between 1996-98 and 1999-2001: Patterns of Care Study for Prostate Cancer Jpn. J. Clin. Oncol., October 1, 2006; 36(10): 649 - 654. [Abstract] [Full Text] [PDF]

				A. K. Lee and A. V. D'Amico Utility of Prostate-Specific Antigen Kinetics in Addition to Clinical Factors in the Selection of Patients for Salvage Local Therapy J. Clin. Oncol., November 10, 2005; 23(32): 8192 - 8197. [Abstract] [Full Text] [PDF]

				A. J. Stephenson and J. A. Eastham Role of Salvage Radical Prostatectomy for Recurrent Prostate Cancer After Radiation Therapy J. Clin. Oncol., November 10, 2005; 23(32): 8198 - 8203. [Abstract] [Full Text] [PDF]

				S. B. Hayes and A. Pollack Parameters for Treatment Decisions for Salvage Radiation Therapy J. Clin. Oncol., November 10, 2005; 23(32): 8204 - 8211. [Abstract] [Full Text] [PDF]

				A. L. Zietman, M. L. DeSilvio, J. D. Slater, C. J. Rossi Jr, D. W. Miller, J. A. Adams, and W. U. Shipley Comparison of Conventional-Dose vs High-Dose Conformal Radiation Therapy in Clinically Localized Adenocarcinoma of the Prostate: A Randomized Controlled Trial JAMA, September 14, 2005; 294(10): 1233 - 1239. [Abstract] [Full Text] [PDF]

				A. V. D'Amico, M.-H. Chen, K. A. Roehl, and W. J. Catalona Identifying Patients at Risk for Significant Versus Clinically Insignificant Postoperative Prostate-Specific Antigen Failure J. Clin. Oncol., August 1, 2005; 23(22): 4975 - 4979. [Abstract] [Full Text] [PDF]

				A. V. D'Amico, A. A. Renshaw, B. Sussman, and M.-H. Chen Pretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy JAMA, July 27, 2005; 294(4): 440 - 447. [Abstract] [Full Text] [PDF]

				H. I. Scher, M. J. Morris, W. K. Kelly, L. H. Schwartz, and G. Heller Prostate Cancer Clinical Trial End Points: "RECIST"ing a Step Backwards Clin. Cancer Res., July 15, 2005; 11(14): 5223 - 5232. [Abstract] [Full Text] [PDF]

				S. Naito Evaluation and Management of Prostate-specific Antigen Recurrence After Radical Prostatectomy for Localized Prostate Cancer Jpn. J. Clin. Oncol., July 1, 2005; 35(7): 365 - 374. [Abstract] [Full Text] [PDF]

				A. B. Jani, M. J. Blend, R. Hamilton, C. Brendler, C. Pelizzari, L. Krauz, B. Sapra, S. Vijayakumar, A. Awan, and R. R. Weichselbaum Radioimmunoscintigraphy for Postprostatectomy Radiotherapy: Analysis of Toxicity and Biochemical Control J. Nucl. Med., August 1, 2004; 45(8): 1315 - 1322. [Abstract] [Full Text] [PDF]

				E. Rosenbaum, A. Partin, and M. A. Eisenberger Biochemical Relapse After Primary Treatment for Prostate Cancer: Studies on Natural History and Therapeutic Considerations J Natl Compr Canc Netw, May 1, 2004; 2(3): 249 - 256. [Abstract] [PDF]

				T. Sella, L. H. Schwartz, P. W. Swindle, C. N. Onyebuchi, P. T. Scardino, H. I. Scher, and H. Hricak Suspected Local Recurrence after Radical Prostatectomy: Endorectal Coil MR Imaging Radiology, May 1, 2004; 231(2): 379 - 385. [Abstract] [Full Text] [PDF]

				A. B. Jani, M. J. Blend, R. Hamilton, C. Brendler, C. Pelizzari, L. Krauz, S. Vijayakumar, B. Sapra, A. Awan, and R. R. Weichselbaum Influence of Radioimmunoscintigraphy on Postprostatectomy Radiotherapy Treatment Decision Making J. Nucl. Med., April 1, 2004; 45(4): 571 - 578. [Abstract] [Full Text] [PDF]

				A. J. Stephenson, S. F. Shariat, M. J. Zelefsky, M. W. Kattan, E. B. Butler, B. S. Teh, E. A. Klein, P. A. Kupelian, C. G. Roehrborn, D. A. Pistenmaa, et al. Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy JAMA, March 17, 2004; 291(11): 1325 - 1332. [Abstract] [Full Text] [PDF]

				A. B. Jani, D. Spelbring, R. Hamilton, M. J. Blend, C. Pelizzari, C. Brendler, L. Krauz, S. Vijayakumar, B. Sapra, and R. R. Weichselbaum Impact of Radioimmunoscintigraphy on Definition of Clinical Target Volume for Radiotherapy After Prostatectomy J. Nucl. Med., February 1, 2004; 45(2): 238 - 246. [Abstract] [Full Text] [PDF]

				S. O. Freytag, H. Stricker, J. Pegg, D. Paielli, D. G. Pradhan, J. Peabody, M. DePeralta-Venturina, X. Xia, S. Brown, M. Lu, et al. Phase I Study of Replication-Competent Adenovirus-Mediated Double-Suicide Gene Therapy in Combination with Conventional-Dose Three-Dimensional Conformal Radiation Therapy for the Treatment of Newly Diagnosed, Intermediate- to High-Risk Prostate Cancer Cancer Res., November 1, 2003; 63(21): 7497 - 7506. [Abstract] [Full Text] [PDF]

				S R J Bott, A J Birtle, C J Taylor, and R S Kirby Prostate cancer management: (1) an update on localised disease Postgrad. Med. J., October 1, 2003; 79(936): 575 - 580. [Abstract] [Full Text] [PDF]

				H. Kattlove and R. J. Winn Ongoing Care of Patients After Primary Treatment for Their Cancer CA Cancer J Clin, May 1, 2003; 53(3): 172 - 196. [Abstract] [Full Text] [PDF]

				M. S. Katz, M. J. Zelefsky, E. S. Venkatraman, Z. Fuks, A. Hummer, and S. A. Leibel Predictors of Biochemical Outcome With Salvage Conformal Radiotherapy After Radical Prostatectomy for Prostate Cancer J. Clin. Oncol., February 1, 2003; 21(3): 483 - 489. [Abstract] [Full Text] [PDF]

				C. Sturgeon Practice Guidelines for Tumor Marker Use in the Clinic Clin. Chem., August 1, 2002; 48(8): 1151 - 1159. [Abstract] [Full Text] [PDF]

				M. J. Haut, J. F. Harryhill, J. Rosenstock, M. J. Warhol, and R. Vitti Progressing Prostate Carcinoma Oncologist, April 1, 2001; 6(2): 183 - 196. [Abstract] [Full Text]